Warnex sells Pathogen Detection System to University of Delaware
Warnex Inc. announced today that the Lasher Laboratory of the University of Delaware, Georgetown, has purchased a Warnex(TM) Rapid Pathogen Detection System to detect Salmonella in poultry.
The Lasher Laboratory provides diagnostic services to the producers of commercial and non-commercial poultry in Delaware, and on the eastern shore of Maryland and Virginia. With a state-of-the-art facility, the laboratory also performs detection assays for new and emerging diseases such as avian influenza, infectious bursal disease, infectious bronchitis, and Newcastle disease. As part of the world-renowned University of Delaware poultry health program, the Lasher Laboratory is committed to support the research, outreach and educational programs of the University, which include interactions with other universities, regulatory agencies, commercial companies and individuals.
The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based technology to rapidly and accurately determine the presence of pathogens in samples. The system allows for the simultaneous detection of multiple pathogens and processing of samples within 12 to 48 hours, a significant improvement over traditional microbiology tests that currently require 5 to 7 days.
About Warnex
Warnex ( www.warnex.ca ) is a publicly traded (TSX: WNX – News) Canadian biotechnology company devoted to protecting public health by providing advanced diagnostic and quality control products and services to the pharmaceutical, agri-food, and healthcare sectors. Warnex’s genomics-based technology offers a versatile detection platform that produces accurate results rapidly, using Real-Time PCR technology combined with unique genetic markers and software. Applications range from pathogen detection in foods and GMO testing to farm-to-fork traceability using Molecular Bar Codes. Our development pipeline includes applications in the detection of viruses, toxins, yeasts, and fungi, as well as meat speciation and bioterrorism. Warnex’s profitable and growing analytical, bioanalytical, and clinical service groups offer a variety of quality control services, method development and validation, contract R&D, bioavailability and bioequivalence studies for clinical trials, and medical laboratory testing.
Warnex is a trademark of Warnex Inc.
